Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

NCT04892498 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Advanced Refractory Solid Tumors

Interventions

RADIATION: Hypofractionated radiotherapy
DRUG: PD-1 inhibitor
DRUG: GM-CSF
DRUG: IL-2

Sponsor

Second Affiliated Hospital of Soochow University